What kind of company is WuXi AppTec?

Wealthcare is China's largest and globally ranked small molecule pharmaceutical research and development services company, with its main business comprising two segments: preclinical CRO and CMO/CDMO.

Wealthcare's main business maintains stable growth, with annual revenue of 12.872 billion in 2019, up 33.89% year-on-year, and non-deductible net profit of 1.914 billion, up 22.82% year-on-year.

Warmin Kinder has more than 3,900 active customers in 2019, and its main customers cover the world's top 20 large pharmaceutical companies and all kinds of new drug research and development organizations, and from the company's top ten customers in the past years, the company's main customers are basically stable, all of them are multinational pharmaceutical giants, and the company does not have a significant dependence on a single customer, and the company's business capacity is stable.

PharmaTech's main business

PharmaTech's main business can be divided into two parts, including preclinical CRO and CMO/CDMO, CRO is known in English as Contract Research Organization, which translates to "Contract Research Organization".

It is in order to reduce costs and improve competitiveness, drug companies gradually delegate the time-consuming and laborious work in new drug development in the form of contracts to specialized organizations for research and development.

Wealthcare's other main business, CMO, is known as Contact Manufacturing Organization (CMO), which translates to "pharmaceutical manufacturing outsourcing service enterprise" in Chinese. CMOs outsource the "mass production" of pharmaceuticals on a contractual basis. The creation of these outsourcing business models is essentially the inevitable product of the social division of labor, making the overall cost of new drug development lower and more efficient.